The prognosis of early-stage renal pelvis cancer is relatively good, and it is possible to achieve clinical recovery after active treatment, but it varies from person to person, and some studies say that its 1-year recurrence-free survival rate is about 90%, and its 1-year tumor-specific survival rate is about 92%. Early stage renal pelvis cancer mostly refers to non-muscle invasive upper urinary tract uroepithelial cancer, and without lymph node and distant metastasis. At this time, the tumor tissue is more limited and metastasis usually does not occur, which is easier to control after active treatment. Renal pelvis cancer originates from urinary tract epithelium, and its biological characteristics are multi-site occurrence and easy recurrence. Since the mucosa of ureter and bladder is also urinary tract epithelium, renal pelvis cancer is often accompanied with tumors of ureter and bladder. Therefore, its treatment mainly consists of surgery, and radical surgery for renal pelvis cancer is often performed to remove half of the urinary tract, including the affected side of the kidney, all of the ureter, and part of the bladder. After surgery, it needs to receive intravesical instillation chemotherapy or immunotherapy (such as epirubicin, BCG, etc.) according to the situation, so as to reduce the tumor recurrence rate. Some studies in China claimed that the median time for recurrence of renal pelvis cancer after surgery was 12 months (i.e., the time for 50% of patients to recur), and 17.2% of patients experienced recurrence, of which 80% of recurrence patients appeared within 2 years after surgery. However, there are no clear conclusions yet. Some studies also claim that the 1-year recurrence-free survival rate of early-stage renal pelvis cancer is about 90%, while the 1-year tumor-specific survival rate is about 92%. In conclusion, renal pelvis cancer is prone to recurrence after surgery and requires regular review. It is recommended that postoperative renal pelvis cancer patients should go to regular hospitals to evaluate their conditions, cooperate with treatments (e.g. cyst infusion chemotherapy, etc.) as prescribed by doctors, and actively follow the doctor’s instructions to review their conditions, and treat any abnormality positively so as to avoid delaying their conditions.